Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -107.29% is 170% below its 5-year average of -39.69%, near the low end of its 5-year range (-107.29%–-14.33%).
77.59% below its 12-month average of -60.42%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -24.73%.
RETURN ON ASSETS (ROA)
-107.29%
RETURN ON ASSETS (ROA) AVG TTM
-60.42%
RETURN ON ASSETS (ROA) AVG 3Y
-51.23%
RETURN ON ASSETS (ROA) AVG 5Y
-39.69%
RETURN ON ASSETS (ROA) AVG 10Y
-73.65%
RETURN ON ASSETS (ROA) AVG 15Y
-81.19%
RETURN ON ASSETS (ROA) AVG 20Y
-81.19%
CURRENT VS TTM AVG
-77.59%
CURRENT VS 3Y AVG
-109.45%
CURRENT VS 5Y AVG
-170.31%
CURRENT VS 10Y AVG
-45.68%
CURRENT VS 15Y AVG
-32.15%
CURRENT VS 20Y AVG
-32.15%
SECTOR MEDIAN · HEALTHCARE
-30.70%
median of 715 covered companies
CURRENT VS SECTOR MEDIAN
-249.48%
vs the sector median at left
Cardiff Oncology, Inc.
Market Cap
$84.78M
Return on Assets (ROA)
-107.29%
TTM Avg
-60.42%
3Y Avg
-51.23%
5Y Avg
-39.69%
Market Cap
$84.57M
Return on Assets (ROA)
-74.48%
TTM Avg
-208.94%
3Y Avg
-35981.57%
5Y Avg
-24064.76%
Market Cap
$85.01M
Return on Assets (ROA)
-43.13%
TTM Avg
-80.45%
3Y Avg
-58.18%
5Y Avg
-65.67%
Market Cap
$84.18M
Return on Assets (ROA)
-70.05%
TTM Avg
-71.47%
3Y Avg
-58.80%
5Y Avg
-51.13%
Market Cap
$83.48M
Return on Assets (ROA)
-41.09%
TTM Avg
-24.80%
3Y Avg
-25.41%
5Y Avg
-25.41%
Market Cap
$83.04M
Return on Assets (ROA)
-74.91%
TTM Avg
-50.52%
3Y Avg
-40.48%
5Y Avg
-70.00%
Market Cap
$86.81M
Return on Assets (ROA)
-79.38%
TTM Avg
41.63%
3Y Avg
-36.06%
5Y Avg
-44.84%
Market Cap
$82.45M
Return on Assets (ROA)
-26.59%
TTM Avg
-23.05%
3Y Avg
-19.50%
5Y Avg
-17.99%
Market Cap
$86.90M
Return on Assets (ROA)
8.52%
TTM Avg
11.64%
3Y Avg
-8.81%
5Y Avg
-6.61%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | $84.78M | -107.29% | -60.42% | -51.23% | -39.69% |
| ProMIS Neurosciences, Inc. (PMN)vs › | $84.57M | -74.48% | -208.94% | -35981.57% | -24064.76% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $85.01M | -43.13% | -80.45% | -58.18% | -65.67% |
| Humacyte, Inc. (HUMA)vs › | $84.18M | -70.05% | -71.47% | -58.80% | -51.13% |
| Citius Oncology, Inc. (CTOR)vs › | $83.48M | -41.09% | -24.80% | -25.41% | -25.41% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $83.04M | -74.91% | -50.52% | -40.48% | -70.00% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $86.81M | -79.38% | 41.63% | -36.06% | -44.84% |
| MediciNova, Inc. (MNOV)vs › | $82.45M | -26.59% | -23.05% | -19.50% | -17.99% |
| CareCloud, Inc. (CCLD)vs › | $86.90M | 8.52% | 11.64% | -8.81% | -6.61% |
| LENSAR Inc (LNSR)vs › | $82.53M | 49.88% | -47.68% | -37.92% | -34.36% |
ROA
-107.3%
ROE
-150.9%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -74.09% |
| 2024-12-31 | -46.74% |
| 2023-12-31 | -50.76% |
| 2022-12-31 | -33.31% |
| 2021-12-31 | -18.92% |
| 2020-12-31 | -14.33% |
| 2019-12-31 | -125.43% |
| 2018-12-31 | -116.15% |
| 2017-12-31 | -202.74% |
| 2016-12-31 | -89.20% |
| 2015-12-31 | -38.45% |
| 2014-12-31 | -49.57% |
| 2013-12-31 | -43.49% |
| 2012-12-31 | -99.15% |
| 2011-12-31 | -215.46% |
| 2010-12-31 | -1063.82% |
| 2009-12-31 | -326.32% |
| 2006-01-31 | 141.13% |
| 2005-01-31 | 503.77% |
